Business
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6
Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to invite investors to a webinar on January 6, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Jupiter Neuroscience Chairman and CEO Chister Rosén who will provide investors with an overview of Jupiter Neurosciences’ scientific
About this update from Jupiter Neurosciences, Inc.
[{"type":"image","alt":"Jupiter Neurosciences, Inc.","displaySize":"","headline":null,"caption":"Jupiter Neurosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/5207be81de89b7ef2fba669f8dd3e7f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pYMq4mt4Y617fyJqYqyXSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5207be81de89b7ef2fba669f8dd3e7f6","width":300,"height":89}},"lazy":false},{"type":"text","content":"Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to invite investors to a webinar on January 6, 2026, at 4:15 p.m. ET.","length":304,"tagName":"p"},{"type":"text","content":"The exclusive event, hosted by RedChip Companies, will feature Jupiter Neuroscience Chairman and CEO Chister Rosén who will provide investors with an overview of Jupiter Neurosciences’ scientific platform, clinical development plans, and commercial strategy heading into 2026. Rosén will discuss the Company’s lead asset, JOTROL™, including its differentiated bioavailability profile and upcoming Phase 2a clinical trial in Parkinson’s disease, as well as the broader therapeutic potential across neuroinflammatory and rare disease indications. The presentation will also outline Jupiter’s dual-path approach, highlighting the launch and early commercialization of its Nugevia™ longevity product line, the rationale for leveraging the same clinically validated technology across pharmaceutical and consumer markets, and how recent financing initiatives support disciplined execution across both pathways.","length":904,"tagName":"p"},{"type":"text","content":"A live Q&A session will follow the presentation.","length":52,"tagName":"p"},{"type":"text","content":"To register for the free webinar, please visit: https://www.redchip.com/webinar/JUNS/86401333631","length":96,"tagName":"p"},{"type":"text","content":"Questions can be pre-submitted to [email protected] or online during the live event.","length":83,"tagName":"p"},{"type":"text","content":"About Jupiter Neurosciences, Inc.","length":33,"tagName":"p"},{"type":"text","content":"Jupiter Neurosciences ...